New medical options for liver tumours

Williams, Sarah; Palmer, Daniel H.; Johnson, Philip J.

doi:10.7861/clinmedicine.7-4-351

Cited by 3 publications

(3 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The management of HCC that is considered too extensive for surgical resection or RFA, poses a difficult and unresolved dilemma in the role of therapeutic choices to assist in palliative care1,2,19,20 In recent years, a strategy of choice is the direct delivery of chemotherapy via the hepatic artery directly to the tumor vasculature2,14,15,20 The present clinical experience was obtained in 2 sequential cohorts of patients with unresectable, advanced HCC. In the first group, we describe our overall experience of patients treated with a structured protocol of cisplatin infusion, accompanied by gelfoam or Embospheres arterial embolization, which was designed to reduce but not completely obstruct (embolize)14 the hepatic arterial blood flow and to minimize side effects (TACE group).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma

Carr

Kondragunta

Buch

et al. 2010

Cancer

171

107

View full text Add to dashboard Cite

BACKGROUND: Intrahepatic arterial yttrium 90 ( 90 Y) microspheres have been proposed as a less toxic, less invasive therapeutic option to transhepatic arterial chemoembolization (TACE) for patients with surgically unresectable hepatocellular carcinoma (HCC). TACE has demonstrated the ability to prolong survival. However, long-term survival remains uncertain. METHODS: In a 2-cohort experience in the treatment of North American patients who had advanced, unresectable, biopsy-proven HCC, 691 patients received repetitive, cisplatin-based chemoembolization; and a separate cohort of 99 patients who had similar treatment criteria received a planned, single dose of 90 Y. Over the study period, an additional 142 patients were followed without treatment (total, 932 patients). RESULTS: Overall survival was slightly better in the 90 Y group compared with the TACE group (median survival, 11.5 months vs 8.5 months). However, the selection criteria indicated a small but significant bias toward milder disease in the 90 Y group. By using stratification into a 3-tier model with patients dichotomized according to bilirubin levels <1.5 mg/dL, the absence of portal vein thrombosis (PVT), and low a-fetoprotein plasma levels (<25 U/dL), an analysis of survival in clinical subgroups indicated that the 2 treatments resulted in similar survival. In addition, patients who had PVT or high afetoprotein levels also had similar survival in both treatment groups. CONCLUSIONS: Given the current evidence of therapeutic equivalence in survival, 90 Y and TACE appeared to be equivalent regional therapies for patients with unresectable, nonmetastatic HCC.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma

Carr

Kondragunta

Buch

et al. 2010

Cancer

171

107

View full text Add to dashboard Cite

show abstract

“…Reynaert and Colle, summarized WHO 2018 statistics analysis and reported that liver cancer is the sixth frequent type of cancer with the 4th leading cause of cancer-related death worldwide and also indicated an increasing trend of incidence and death rat [ 389 ]. Many other primary cancers metastasize into the liver, the most notable being the colorectal cancer [ 390 ]. At the early stage of tumour surgical eradication of the tumour is the treatment of choice in 30% of the HCC cases.…”

Section: Somatostatin and Liver Cancermentioning

confidence: 99%

Somatostatin and Somatostatin Receptors in Tumour Biology

Kumar

2023

IJMS

View full text Add to dashboard Cite

Somatostatin (SST), a growth hormone inhibitory peptide, is expressed in endocrine and non-endocrine tissues, immune cells and the central nervous system (CNS). Post-release from secretory or immune cells, the first most appreciated role that SST exhibits is the antiproliferative effect in target tissue that served as a potential therapeutic intervention in various tumours of different origins. The SST-mediated in vivo and/or in vitro antiproliferative effect in the tumour is considered direct via activation of five different somatostatin receptor subtypes (SSTR1-5), which are well expressed in most tumours and often more than one receptor in a single cell. Second, the indirect effect is associated with the regulation of growth factors. SSTR subtypes are crucial in tumour diagnosis and prognosis. In this review, with the recent development of new SST analogues and receptor-specific agonists with emerging functional consequences of signaling pathways are promising therapeutic avenues in tumours of different origins that are discussed.

show abstract

“…There is some evidence for survival benefit, but only in very carefully selected patients. [ 44 ] The systemic therapy using chemotherapy, immunotherapy, hormonal therapy or somatostatin analog have been disappointing in patients with advanced HCC. [ 45 ] Since HCC is a hypervascular cancer, gene therapy may be used for anti-angiogenesis to reduce tumor growth, and is a promising approach to treat HCC.…”

Section: Relation Between Hepatitis C and Hepatocellular Carcinomamentioning

confidence: 99%

Association between hepatitis C and hepatocellular carcinoma

Andrade

Júnior

Melo

et al. 2009

J Global Infect Dis

143

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fifth most common cancer, the third most common cause for cancer death in the world, a major cause of death in patients with chronic hepatitis C virus infection, and responsible for approximately one million deaths each year. Overwhelming lines of epidemiological evidence have indicated that persistent infection with hepatitis C virus (HCV) is a major risk for the development of HCC. The incidence of HCC is expected to increase in the next two decades, largely due to hepatitis C infection and secondary cirrhosis, and detection of HCC at an early stage is critical for a favorable clinical outcome. Potential preventive strategies in the development of HCC are being recognized. The natural history of HCC is highly variable and the clinical management choices for HCC can be complex, hence patient assessment and treatment planning have to take the severity of the nonmalignant liver disease into account. This review summarizes the inter-relationship between HCV and liver carcinogenesis.

show abstract

New medical options for liver tumours

Cited by 3 publications

References 33 publications

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma

Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma

Somatostatin and Somatostatin Receptors in Tumour Biology

Association between hepatitis C and hepatocellular carcinoma

Contact Info

Product

Resources

About